Patient demographics
| . | Placebo (n = 21) . | Montelukast (n = 20) . | P . |
|---|---|---|---|
| Male, n (%) | 8 (38) | 9 (45) | .76 |
| Age, median (range), y | 27 (19-52) | 26.5 (16-64) | .96 |
| Hospitalizations in last 3 y, n | 2 (0-3) | 3 (1.5-7) | .13 |
| ED visits in last 3 y, n | 2 (1-4) | 5 (1.5-7) | .16 |
| Admissions for pain crises in last 3 y, n | 7.5 (4-15) | 10 (6.5-20) | .46 |
| WBC, ×109/L | 7.1 (5.5-8.6) | 7.6 (5.5-9.4) | .50 |
| Hb, g/dL | 8.7 (8.2-9.7) | 9.1 (8.3-9.9) | .34 |
| Reticulocyte count (%), % | 8.85 (5.50-13.1) | 9.15 (8.35-9.9) | .53 |
| . | Placebo (n = 21) . | Montelukast (n = 20) . | P . |
|---|---|---|---|
| Male, n (%) | 8 (38) | 9 (45) | .76 |
| Age, median (range), y | 27 (19-52) | 26.5 (16-64) | .96 |
| Hospitalizations in last 3 y, n | 2 (0-3) | 3 (1.5-7) | .13 |
| ED visits in last 3 y, n | 2 (1-4) | 5 (1.5-7) | .16 |
| Admissions for pain crises in last 3 y, n | 7.5 (4-15) | 10 (6.5-20) | .46 |
| WBC, ×109/L | 7.1 (5.5-8.6) | 7.6 (5.5-9.4) | .50 |
| Hb, g/dL | 8.7 (8.2-9.7) | 9.1 (8.3-9.9) | .34 |
| Reticulocyte count (%), % | 8.85 (5.50-13.1) | 9.15 (8.35-9.9) | .53 |
Hb, hemoglobin; WBC, white blood cell count.
Unless otherwise noted, data are median (IQR).